The global market for Proliferative Diabetic Retinopathy was valued at US$ 1902 million in the year 2024 and is projected to reach a revised size of US$ 3256 million by 2031, growing at a CAGR of 8.1% during the forecast period.

Proliferative Diabetic Retinopathy Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Proliferative Diabetic Retinopathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Proliferative Diabetic Retinopathy.

The Proliferative Diabetic Retinopathy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Proliferative Diabetic Retinopathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Proliferative Diabetic Retinopathy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Proliferative Diabetic Retinopathy Market Report

Report Metric	Details
Report Name	Proliferative Diabetic Retinopathy Market
Accounted market size in year	US$ 1902 million
Forecasted market size in 2031	US$ 3256 million
CAGR	8.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Anti-VEGF Agents Corticosteroids
Segment by Application	Hospitals Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Intas Pharmaceuticals, Santen Pharmaceutical, Bausch Health, Allergan Plc, Regeneron Pharmaceuticals, Merck KGaA, Cipla, Genentech, Inc. (Roche Holdings), Novartis, Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Proliferative Diabetic Retinopathy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Proliferative Diabetic Retinopathy Market growing?

Ans: The Proliferative Diabetic Retinopathy Market witnessing a CAGR of 8.1% during the forecast period 2025-2031.

What is the Proliferative Diabetic Retinopathy Market size in 2031?

Ans: The Proliferative Diabetic Retinopathy Market size in 2031 will be US$ 3256 million.

Who are the main players in the Proliferative Diabetic Retinopathy Market report?

Ans: The main players in the Proliferative Diabetic Retinopathy Market are Intas Pharmaceuticals, Santen Pharmaceutical, Bausch Health, Allergan Plc, Regeneron Pharmaceuticals, Merck KGaA, Cipla, Genentech, Inc. (Roche Holdings), Novartis, Pfizer

What are the Application segmentation covered in the Proliferative Diabetic Retinopathy Market report?

Ans: The Applications covered in the Proliferative Diabetic Retinopathy Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Proliferative Diabetic Retinopathy Market report?

Ans: The Types covered in the Proliferative Diabetic Retinopathy Market report are Anti-VEGF Agents, Corticosteroids

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Proliferative Diabetic Retinopathy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Anti-VEGF Agents

1.2.3 Corticosteroids

1.3 Market by Application

1.3.1 Global Proliferative Diabetic Retinopathy Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Proliferative Diabetic Retinopathy Market Perspective (2020-2031)

2.2 Global Proliferative Diabetic Retinopathy Growth Trends by Region

2.2.1 Global Proliferative Diabetic Retinopathy Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Proliferative Diabetic Retinopathy Historic Market Size by Region (2020-2025)

2.2.3 Proliferative Diabetic Retinopathy Forecasted Market Size by Region (2026-2031)

2.3 Proliferative Diabetic Retinopathy Market Dynamics

2.3.1 Proliferative Diabetic Retinopathy Industry Trends

2.3.2 Proliferative Diabetic Retinopathy Market Drivers

2.3.3 Proliferative Diabetic Retinopathy Market Challenges

2.3.4 Proliferative Diabetic Retinopathy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Proliferative Diabetic Retinopathy Players by Revenue

3.1.1 Global Top Proliferative Diabetic Retinopathy Players by Revenue (2020-2025)

3.1.2 Global Proliferative Diabetic Retinopathy Revenue Market Share by Players (2020-2025)

3.2 Global Proliferative Diabetic Retinopathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Proliferative Diabetic Retinopathy Revenue

3.4 Global Proliferative Diabetic Retinopathy Market Concentration Ratio

3.4.1 Global Proliferative Diabetic Retinopathy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Proliferative Diabetic Retinopathy Revenue in 2024

3.5 Global Key Players of Proliferative Diabetic Retinopathy Head office and Area Served

3.6 Global Key Players of Proliferative Diabetic Retinopathy, Product and Application

3.7 Global Key Players of Proliferative Diabetic Retinopathy, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Proliferative Diabetic Retinopathy Breakdown Data by Type

4.1 Global Proliferative Diabetic Retinopathy Historic Market Size by Type (2020-2025)

4.2 Global Proliferative Diabetic Retinopathy Forecasted Market Size by Type (2026-2031)

5 Proliferative Diabetic Retinopathy Breakdown Data by Application

5.1 Global Proliferative Diabetic Retinopathy Historic Market Size by Application (2020-2025)

5.2 Global Proliferative Diabetic Retinopathy Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Proliferative Diabetic Retinopathy Market Size (2020-2031)

6.2 North America Proliferative Diabetic Retinopathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Proliferative Diabetic Retinopathy Market Size by Country (2020-2025)

6.4 North America Proliferative Diabetic Retinopathy Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Proliferative Diabetic Retinopathy Market Size (2020-2031)

7.2 Europe Proliferative Diabetic Retinopathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Proliferative Diabetic Retinopathy Market Size by Country (2020-2025)

7.4 Europe Proliferative Diabetic Retinopathy Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Proliferative Diabetic Retinopathy Market Size (2020-2031)

8.2 Asia-Pacific Proliferative Diabetic Retinopathy Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Proliferative Diabetic Retinopathy Market Size by Region (2020-2025)

8.4 Asia-Pacific Proliferative Diabetic Retinopathy Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Proliferative Diabetic Retinopathy Market Size (2020-2031)

9.2 Latin America Proliferative Diabetic Retinopathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Proliferative Diabetic Retinopathy Market Size by Country (2020-2025)

9.4 Latin America Proliferative Diabetic Retinopathy Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Proliferative Diabetic Retinopathy Market Size (2020-2031)

10.2 Middle East & Africa Proliferative Diabetic Retinopathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Proliferative Diabetic Retinopathy Market Size by Country (2020-2025)

10.4 Middle East & Africa Proliferative Diabetic Retinopathy Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Intas Pharmaceuticals

11.1.1 Intas Pharmaceuticals Company Details

11.1.2 Intas Pharmaceuticals Business Overview

11.1.3 Intas Pharmaceuticals Proliferative Diabetic Retinopathy Introduction

11.1.4 Intas Pharmaceuticals Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.1.5 Intas Pharmaceuticals Recent Development

11.2 Santen Pharmaceutical

11.2.1 Santen Pharmaceutical Company Details

11.2.2 Santen Pharmaceutical Business Overview

11.2.3 Santen Pharmaceutical Proliferative Diabetic Retinopathy Introduction

11.2.4 Santen Pharmaceutical Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.2.5 Santen Pharmaceutical Recent Development

11.3 Bausch Health

11.3.1 Bausch Health Company Details

11.3.2 Bausch Health Business Overview

11.3.3 Bausch Health Proliferative Diabetic Retinopathy Introduction

11.3.4 Bausch Health Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.3.5 Bausch Health Recent Development

11.4 Allergan Plc

11.4.1 Allergan Plc Company Details

11.4.2 Allergan Plc Business Overview

11.4.3 Allergan Plc Proliferative Diabetic Retinopathy Introduction

11.4.4 Allergan Plc Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.4.5 Allergan Plc Recent Development

11.5 Regeneron Pharmaceuticals

11.5.1 Regeneron Pharmaceuticals Company Details

11.5.2 Regeneron Pharmaceuticals Business Overview

11.5.3 Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Introduction

11.5.4 Regeneron Pharmaceuticals Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.5.5 Regeneron Pharmaceuticals Recent Development

11.6 Merck KGaA

11.6.1 Merck KGaA Company Details

11.6.2 Merck KGaA Business Overview

11.6.3 Merck KGaA Proliferative Diabetic Retinopathy Introduction

11.6.4 Merck KGaA Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.6.5 Merck KGaA Recent Development

11.7 Cipla

11.7.1 Cipla Company Details

11.7.2 Cipla Business Overview

11.7.3 Cipla Proliferative Diabetic Retinopathy Introduction

11.7.4 Cipla Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.7.5 Cipla Recent Development

11.8 Genentech, Inc. (Roche Holdings)

11.8.1 Genentech, Inc. (Roche Holdings) Company Details

11.8.2 Genentech, Inc. (Roche Holdings) Business Overview

11.8.3 Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Introduction

11.8.4 Genentech, Inc. (Roche Holdings) Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.8.5 Genentech, Inc. (Roche Holdings) Recent Development

11.9 Novartis

11.9.1 Novartis Company Details

11.9.2 Novartis Business Overview

11.9.3 Novartis Proliferative Diabetic Retinopathy Introduction

11.9.4 Novartis Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.9.5 Novartis Recent Development

11.10 Pfizer

11.10.1 Pfizer Company Details

11.10.2 Pfizer Business Overview

11.10.3 Pfizer Proliferative Diabetic Retinopathy Introduction

11.10.4 Pfizer Revenue in Proliferative Diabetic Retinopathy Business (2020-2025)

11.10.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Intas Pharmaceuticals

Santen Pharmaceutical

Bausch Health

Allergan plc

Regeneron Pharmaceuticals

Merck KGaA

Cipla Ltd

Genentech, Inc. (Roche Holdings)

Novartis

Pfizer Inc

List of Tables

Table 1. Global Proliferative Diabetic Retinopathy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Anti-VEGF Agents

Table 3. Key Players of Corticosteroids

Table 4. Global Proliferative Diabetic Retinopathy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Proliferative Diabetic Retinopathy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Proliferative Diabetic Retinopathy Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Proliferative Diabetic Retinopathy Market Share by Region (2020-2025)

Table 8. Global Proliferative Diabetic Retinopathy Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Proliferative Diabetic Retinopathy Market Share by Region (2026-2031)

Table 10. Proliferative Diabetic Retinopathy Market Trends

Table 11. Proliferative Diabetic Retinopathy Market Drivers

Table 12. Proliferative Diabetic Retinopathy Market Challenges

Table 13. Proliferative Diabetic Retinopathy Market Restraints

Table 14. Global Proliferative Diabetic Retinopathy Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Proliferative Diabetic Retinopathy Market Share by Players (2020-2025)

Table 16. Global Top Proliferative Diabetic Retinopathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Proliferative Diabetic Retinopathy as of 2024)

Table 17. Ranking of Global Top Proliferative Diabetic Retinopathy Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Proliferative Diabetic Retinopathy Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Proliferative Diabetic Retinopathy, Headquarters and Area Served

Table 20. Global Key Players of Proliferative Diabetic Retinopathy, Product and Application

Table 21. Global Key Players of Proliferative Diabetic Retinopathy, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Proliferative Diabetic Retinopathy Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Proliferative Diabetic Retinopathy Revenue Market Share by Type (2020-2025)

Table 25. Global Proliferative Diabetic Retinopathy Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Proliferative Diabetic Retinopathy Revenue Market Share by Type (2026-2031)

Table 27. Global Proliferative Diabetic Retinopathy Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Proliferative Diabetic Retinopathy Revenue Market Share by Application (2020-2025)

Table 29. Global Proliferative Diabetic Retinopathy Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Proliferative Diabetic Retinopathy Revenue Market Share by Application (2026-2031)

Table 31. North America Proliferative Diabetic Retinopathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Proliferative Diabetic Retinopathy Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Proliferative Diabetic Retinopathy Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Proliferative Diabetic Retinopathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Proliferative Diabetic Retinopathy Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Proliferative Diabetic Retinopathy Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Proliferative Diabetic Retinopathy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Proliferative Diabetic Retinopathy Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Proliferative Diabetic Retinopathy Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Proliferative Diabetic Retinopathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Proliferative Diabetic Retinopathy Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Proliferative Diabetic Retinopathy Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Proliferative Diabetic Retinopathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Proliferative Diabetic Retinopathy Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Proliferative Diabetic Retinopathy Market Size by Country (2026-2031) & (US$ Million)

Table 46. Intas Pharmaceuticals Company Details

Table 47. Intas Pharmaceuticals Business Overview

Table 48. Intas Pharmaceuticals Proliferative Diabetic Retinopathy Product

Table 49. Intas Pharmaceuticals Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 50. Intas Pharmaceuticals Recent Development

Table 51. Santen Pharmaceutical Company Details

Table 52. Santen Pharmaceutical Business Overview

Table 53. Santen Pharmaceutical Proliferative Diabetic Retinopathy Product

Table 54. Santen Pharmaceutical Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 55. Santen Pharmaceutical Recent Development

Table 56. Bausch Health Company Details

Table 57. Bausch Health Business Overview

Table 58. Bausch Health Proliferative Diabetic Retinopathy Product

Table 59. Bausch Health Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 60. Bausch Health Recent Development

Table 61. Allergan Plc Company Details

Table 62. Allergan Plc Business Overview

Table 63. Allergan Plc Proliferative Diabetic Retinopathy Product

Table 64. Allergan Plc Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 65. Allergan Plc Recent Development

Table 66. Regeneron Pharmaceuticals Company Details

Table 67. Regeneron Pharmaceuticals Business Overview

Table 68. Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Product

Table 69. Regeneron Pharmaceuticals Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 70. Regeneron Pharmaceuticals Recent Development

Table 71. Merck KGaA Company Details

Table 72. Merck KGaA Business Overview

Table 73. Merck KGaA Proliferative Diabetic Retinopathy Product

Table 74. Merck KGaA Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 75. Merck KGaA Recent Development

Table 76. Cipla Company Details

Table 77. Cipla Business Overview

Table 78. Cipla Proliferative Diabetic Retinopathy Product

Table 79. Cipla Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 80. Cipla Recent Development

Table 81. Genentech, Inc. (Roche Holdings) Company Details

Table 82. Genentech, Inc. (Roche Holdings) Business Overview

Table 83. Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Product

Table 84. Genentech, Inc. (Roche Holdings) Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 85. Genentech, Inc. (Roche Holdings) Recent Development

Table 86. Novartis Company Details

Table 87. Novartis Business Overview

Table 88. Novartis Proliferative Diabetic Retinopathy Product

Table 89. Novartis Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 90. Novartis Recent Development

Table 91. Pfizer Company Details

Table 92. Pfizer Business Overview

Table 93. Pfizer Proliferative Diabetic Retinopathy Product

Table 94. Pfizer Revenue in Proliferative Diabetic Retinopathy Business (2020-2025) & (US$ Million)

Table 95. Pfizer Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

Table 99. Authors List of This Report

List of Figures

Figure 1. Proliferative Diabetic Retinopathy Picture

Figure 2. Global Proliferative Diabetic Retinopathy Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Proliferative Diabetic Retinopathy Market Share by Type: 2024 VS 2031

Figure 4. Anti-VEGF Agents Features

Figure 5. Corticosteroids Features

Figure 6. Global Proliferative Diabetic Retinopathy Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Proliferative Diabetic Retinopathy Market Share by Application: 2024 VS 2031

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Others Case Studies

Figure 11. Proliferative Diabetic Retinopathy Report Years Considered

Figure 12. Global Proliferative Diabetic Retinopathy Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Proliferative Diabetic Retinopathy Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Proliferative Diabetic Retinopathy Market Share by Region: 2024 VS 2031

Figure 15. Global Proliferative Diabetic Retinopathy Market Share by Players in 2024

Figure 16. Global Top Proliferative Diabetic Retinopathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Proliferative Diabetic Retinopathy as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Proliferative Diabetic Retinopathy Revenue in 2024

Figure 18. North America Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Proliferative Diabetic Retinopathy Market Share by Country (2020-2031)

Figure 20. United States Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Proliferative Diabetic Retinopathy Market Share by Country (2020-2031)

Figure 24. Germany Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Proliferative Diabetic Retinopathy Market Share by Region (2020-2031)

Figure 32. China Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Proliferative Diabetic Retinopathy Market Share by Country (2020-2031)

Figure 40. Mexico Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Proliferative Diabetic Retinopathy Market Share by Country (2020-2031)

Figure 44. Turkey Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Proliferative Diabetic Retinopathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Intas Pharmaceuticals Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 48. Santen Pharmaceutical Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 49. Bausch Health Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 50. Allergan Plc Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 51. Regeneron Pharmaceuticals Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 52. Merck KGaA Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 53. Cipla Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 54. Genentech, Inc. (Roche Holdings) Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 55. Novartis Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 56. Pfizer Revenue Growth Rate in Proliferative Diabetic Retinopathy Business (2020-2025)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions